Proton RBE rose sharply beyond the Bragg peak in pancreatic cancer cells

In two PDAC cell lines, measured proton RBE remained near 1.0 through the Bragg peak but rose as high as 6.1 distally.

KEY POINTS

  • Investigators measured proton biological effectiveness in Panc-1 and COLO 357 FG pancreatic ductal adenocarcinoma cells using a high-throughput 96-well platform sampling 12 discrete depths along an 81.4-MeV pristine proton Bragg curve.
  • Radiation quality was characterized using dose-mean lineal energy, ranging from 1.9 to 20.0 keV/µm across the proton positions; parallel 6-MV photons at 0.8 keV/µm served as the biological reference.
  • At approximately equal physical dose, biological response changed markedly with radiation quality: wells receiving about 5.4 Gy at 6.2 keV/µm showed substantially greater surviving cell density than wells receiving 5.3 Gy at 16.3 keV/µm near the distal region.
  • RBE at 10% viability remained around 1.0 through the entrance and Bragg-peak region, then increased rapidly distally. In Panc-1 cells, RBE rose to 1.57 at 14.8, 3.03 at 18.7, and 4.56 at 20.0 keV/µm.
  • COLO 357 FG showed an even steeper rise: RBE reached 1.59, 3.61, and 6.05 at the same three positions. The difference between the two cell lines was not statistically significant at individual positions because confidence intervals overlapped.
  • COLO 357 FG also showed an unusual approximately linear proton dose-response with a near-zero quadratic component, despite demonstrating a conventional linear-quadratic response to photons, suggesting potentially different repair behavior with higher-quality proton exposures.
  • These very high RBE values should not be transferred directly into clinical plans. The experiment used a pristine Bragg curve; clinical spread-out Bragg peaks generally have lower lineal energies around 5–10 keV/µm, and the endpoint was crystal-violet proliferation rather than clonogenic survival.

CLINICAL TAKEAWAY

A fixed proton RBE of 1.1 clearly does not describe every microscopic region of a proton beam, and the distal edge deserves particular biological attention in PDAC as well as adjacent normal tissues. This is mechanistic laboratory evidence, not a justification for changing clinical prescriptions or intentionally creating high-RBE hotspots.

SOURCE

Frontiers in Oncology